Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis

Midori Hasegawa, Chikako Nishii, Nao Kabutan, Masao Kato, Atsushi Ohashi, Shigeru Nakai, Kazutaka Murakami, Makoto Tomita, Kunihiro Nabeshima, Yoshiyuki Hiki, Hisaji Oshima, Satoshi Sugiyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

To evaluate the therapeutic potential of cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after cytapheresis might contribute to inhibit the action of TNF-α. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalTherapeutic Apheresis and Dialysis
Volume11
Issue number5
DOIs
Publication statusPublished - 01-10-2007

Fingerprint

Cytapheresis
Tumor Necrosis Factor Receptors
Vasculitis
Autoantibodies
Receptors, Tumor Necrosis Factor, Type I
Peroxidase
Receptors, Tumor Necrosis Factor, Type II
Granulocytes
Respiratory Burst
Therapeutics
Inflammation

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Hasegawa, Midori ; Nishii, Chikako ; Kabutan, Nao ; Kato, Masao ; Ohashi, Atsushi ; Nakai, Shigeru ; Murakami, Kazutaka ; Tomita, Makoto ; Nabeshima, Kunihiro ; Hiki, Yoshiyuki ; Oshima, Hisaji ; Sugiyama, Satoshi. / Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis. In: Therapeutic Apheresis and Dialysis. 2007 ; Vol. 11, No. 5. pp. 337-340.
@article{34d665c5e0aa4a149f3c1e37385a6545,
title = "Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis",
abstract = "To evaluate the therapeutic potential of cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after cytapheresis might contribute to inhibit the action of TNF-α. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.",
author = "Midori Hasegawa and Chikako Nishii and Nao Kabutan and Masao Kato and Atsushi Ohashi and Shigeru Nakai and Kazutaka Murakami and Makoto Tomita and Kunihiro Nabeshima and Yoshiyuki Hiki and Hisaji Oshima and Satoshi Sugiyama",
year = "2007",
month = "10",
day = "1",
doi = "10.1111/j.1744-9987.2007.00496.x",
language = "English",
volume = "11",
pages = "337--340",
journal = "Therapeutic Apheresis and Dialysis",
issn = "1744-9979",
publisher = "Wiley-Blackwell",
number = "5",

}

Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis. / Hasegawa, Midori; Nishii, Chikako; Kabutan, Nao; Kato, Masao; Ohashi, Atsushi; Nakai, Shigeru; Murakami, Kazutaka; Tomita, Makoto; Nabeshima, Kunihiro; Hiki, Yoshiyuki; Oshima, Hisaji; Sugiyama, Satoshi.

In: Therapeutic Apheresis and Dialysis, Vol. 11, No. 5, 01.10.2007, p. 337-340.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of cytapheresis on tumor necrosis factor receptor and on expression of CD63 in myeloperoxidase-antineutrophil cytoplasmic autoantibody-associated vasculitis

AU - Hasegawa, Midori

AU - Nishii, Chikako

AU - Kabutan, Nao

AU - Kato, Masao

AU - Ohashi, Atsushi

AU - Nakai, Shigeru

AU - Murakami, Kazutaka

AU - Tomita, Makoto

AU - Nabeshima, Kunihiro

AU - Hiki, Yoshiyuki

AU - Oshima, Hisaji

AU - Sugiyama, Satoshi

PY - 2007/10/1

Y1 - 2007/10/1

N2 - To evaluate the therapeutic potential of cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after cytapheresis might contribute to inhibit the action of TNF-α. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.

AB - To evaluate the therapeutic potential of cytapheresis in myeloperoxidase-antineutrophil cytoplasmic autoantibody (MPO-ANCA)-associated vasculitis, plasma levels of soluble tumor necrosis factor receptors (sTNFR1, sTNFR2) and the expression of TNFR1, TNFR2, and CD63 on granulocytes were measured. The levels of sTNFR1 and sTNFR2, and the expression of TNFR1 and TNFR2 were significantly higher in MPO-ANCA-associated vasculitis patients than in normal controls. The levels of sTNFR1 and sTNFR2 increased significantly after cytapheresis (P < 0.001). The expression of TNFR1 showed a tendency to decrease after cytapheresis (P = 0.0535). The expression of CD63 decreased significantly after cytapheresis (P < 0.05). Because sTNFR1 and sTNFR2 act as TNF-antagonists, the increases of sTNFR1 and sTNFR2 after cytapheresis might contribute to inhibit the action of TNF-α. The decreased expression of TNFR1, which mediates the signal for polymorphonuclear cell respiratory burst, might also contribute to the reduction of inflammation. From these results, the inhibition of TNF action and removal of degranulated granulocytes appear to be related to the mechanism whereby cytapheresis can exert a beneficial and therapeutic function in the treatment of MPO-ANCA-associated vasculitis.

UR - http://www.scopus.com/inward/record.url?scp=34548528346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548528346&partnerID=8YFLogxK

U2 - 10.1111/j.1744-9987.2007.00496.x

DO - 10.1111/j.1744-9987.2007.00496.x

M3 - Article

C2 - 17845393

AN - SCOPUS:34548528346

VL - 11

SP - 337

EP - 340

JO - Therapeutic Apheresis and Dialysis

JF - Therapeutic Apheresis and Dialysis

SN - 1744-9979

IS - 5

ER -